Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 25 Show results per page	View Search Criteria \| Help With Results

Last Modified: 9/19/2008 First Published: 12/23/2003


1.		Phase III Randomized Study of Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Postmenopausal				NCI				SWOG-S0226 CAN-NCIC-MAC7, S0226, NCT00075764

Last Modified: 9/12/2007 First Published: 11/4/2005


2.		Phase III Randomized Study of Fulvestrant With Versus Without Anastrozole Versus Exemestane Alone in Postmenopausal Women With Estrogen Receptor and/or Progesterone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Relapsed or Progressed During Prior Treatment With Nonsteroidal Aromatase Inhibitors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				Other				ICR-CTSU-SOFEA EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422

Last Modified: 9/19/2008 First Published: 10/14/2006


3.		Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-40302 CALGB-40302, NCT00390455


4.		Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 to 80				Other				GEICAM/2006-10 NCT00543127

First Published: 5/29/2008


5.		Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				GIM-GIM8-OVER GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194

Last Modified: 6/10/2008 First Published: 12/22/2004


6.		Phase II Randomized Study of Erlotinib Hydrochloride With Versus Without Fulvestrant in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				NCI				UCLA-0407058-01 NCT00100854

Last Modified: 6/10/2008 First Published: 8/24/2005


7.		Phase II Randomized Study of Fulvestrant and/or Trastuzumab (Herceptin®) as First-Line Treatment in Postmenopausal Women With Estrogen Receptor and/or Progesterone Receptor-Positive, HER2/neu-Overexpressing Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Postmenopausal				NCI				UCLA-0502057-01 TORI-B-04, NCT00138125

Last Modified: 11/20/2006 First Published: 9/16/2005


8.		Phase II Study of Fulvestrant in Patients With Early Recurrent Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Any age				Pharmaceutical / Industry				RPCI-I-17203 RPCI-PH-17203, ZENECA-IRUSFULV0026, NCT00217464


9.		Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				OSU-0494 NCT00201864


10.		Anti-Tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				9238IL/0057 D6997C00057, NCT00259090

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute